Discover
BNTC
Benitec Biopharma Inc.
8.87
2 x 6.37
2 x 11.27
bid
ask
+
0.12
1.37%
2 @ 06:45 PM
8.88 +0.01 (0.11%)
| Ytd | -34.15% | |
| 1y | -37.54% |
8.71
day range
9.02
8.75
52 week range
16.52
| Open | 8.72 | Prev Close | 8.75 | Low | 8.71 | High | 9.02 | Mkt Cap | 309.41M |
| Vol | 73.14K | Avg Vol | 154.86K | EPS | -0.98 | P/E | N/A | Forward P/E | -1.23 |
| Beta | 0.88 | Short Ratio | 1.35 | Inst. Own | 82.59% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 11.72 | 200-d Avg | 11.85 | 1yr Est | 25.43 |
| Income Statement | |||
| Operating Expenses | 14.43M | ||
| Research and Development Expense | 7.89M | ||
| Selling, General and Administrative Expense | 6.54M | ||
| Operating Income | -14.43M | ||
| Net Income | -12.81M | ||
| Net Income Common Stock | -12.81M | ||
| Net Income Common Stock (USD) | -12.81M | ||
| Consolidated Income | -12.81M | ||
| Earnings per Basic Share | -0.26 | ||
| Earnings per Basic Share (USD) | -0.26 | ||
| Earnings per Diluted Share | -0.26 | ||
| Earning Before Interest & Taxes (EBIT) | -12.81M | ||
| Earning Before Interest & Taxes (USD) | -12.81M | ||
| Weighted Average Shares | 49.44M | ||
| Weighted Average Shares Diluted | 49.44M | ||
| Balance Sheet | |||
| Cash and Equivalents | 180.14M | ||
| Cash and Equivalents (USD) | 180.14M | ||
| Trade and Non-Trade Receivables | 4.00K | ||
| Current Assets | 181.69M | ||
| Property, Plant & Equipment Net | 871.00K | ||
| Total Assets | 182.62M | ||
| Debt Current | 496.00K | ||
| Total Debt | 762.00K | ||
| Current Liabilities | 5.34M | ||
| Debt Non-Current | 266.00K | ||
| Total Liabilities | 5.61M | ||
| Accumulated Retained Earnings (Deficit) | -273.72M | ||
| Accumulated Other Comprehensive Income | -963.00K | ||
| Shareholders Equity | 177.01M | ||
| Shareholders Equity (USD) | 177.01M | ||
| Assets Non-Current | 938.00K | ||
| Total Debt (USD) | 762.00K | ||
| Liabilities Non-Current | 266.00K | ||
| Trade and Non-Trade Payables | 4.30M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 124.00K | ||
| Net Cash Flow from Financing | 241.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -4.79M | ||
| Capital Expenditure | -79.00K | ||
| Issuance (Purchase) of Equity Shares | -6.02M | ||
| Net Cash Flow from Investing | -79.00K | ||
| Net Cash Flow from Operations | -4.94M | ||
| Effect of Exchange Rate Changes on Cash | -12.00K | ||
| Share Based Compensation | 6.26M | ||